港股异动 | 康方生物(09926)早盘涨近5% 曼多奇单抗(IL-4Rα)新药上市申请获受理

智通财经网
Feb 27

智通财经APP获悉,康方生物(09926)早盘涨近5%,截至发稿,涨4.22%,报106.2港元,成交额4.56亿港元。

消息面上,2月25日,康方生物自主研发的IL-4Rα单抗(曼多奇单抗,AK120)已正式向国家药品监督管理局(NMPA)提交上市申请(NDA)并获受理,拟用于治疗中重度特应性皮炎(AD)。

据悉,康方生物的曼多奇单抗是其进入上市申报阶段的第四款非肿瘤药物,此前PCSK9单抗伊努西单抗、IL-12/IL-23单抗依若奇单抗、IL-17A单抗古莫奇单抗已相继获批或申报上市,构建了覆盖心血管代谢、皮肤、关节等多领域的自免产品矩阵

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10